BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37569852)

  • 1. Cytokine-Induced Killer Cells in Combination with Heat Shock Protein 90 Inhibitors Functioning via the Fas/FasL Axis Provides Rationale for a Potential Clinical Benefit in Burkitt's lymphoma.
    Ge F; Wang Y; Sharma A; Yang Y; Liu H; Essler M; Jaehde U; Schmidt-Wolf IGH
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
    Wu X; Sharma A; Oldenburg J; Weiher H; Essler M; Skowasch D; Schmidt-Wolf IGH
    Front Immunol; 2021; 12():731767. PubMed ID: 34691037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.
    Lu X; Zhu A; Cai X; Jia Z; Han W; Ma L; Zhou M; Qian K; Cen L; Chen B
    Cancer Biol Ther; 2012 Jun; 13(8):623-9. PubMed ID: 22555808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD95-mediated apoptosis in Burkitt's lymphoma B-cells is associated with Pim-1 down-regulation.
    Matou-Nasri S; Rabhan Z; Al-Baijan H; Al-Eidi H; Yahya WB; Al Abdulrahman A; Almobadel N; Alsubeai M; Al Ghamdi S; Alaskar A; AlBalwi M; Alzahrani M; Alabdulkareem I
    Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):239-252. PubMed ID: 27641442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
    Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
    Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
    Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
    Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sesamolin enhances NK cell lysis activity by increasing the expression of NKG2D ligands on Burkitt's lymphoma cells.
    Kim JH; Lee JK
    Int Immunopharmacol; 2015 Oct; 28(2):977-84. PubMed ID: 26298637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
    Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
    Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling.
    Walter R; Pan KT; Doebele C; Comoglio F; Tomska K; Bohnenberger H; Young RM; Jacobs L; Keller U; Bönig H; Engelke M; Rosenwald A; Urlaub H; Staudt LM; Serve H; Zenz T; Oellerich T
    Blood; 2017 Feb; 129(5):598-608. PubMed ID: 28064214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells.
    Su X; Zhang L; Jin L; Ye J; Guan Z; Chen R
    J Clin Immunol; 2010 Sep; 30(5):766-74. PubMed ID: 20549316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
    Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
    Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naringenin enhances NK cell lysis activity by increasing the expression of NKG2D ligands on Burkitt's lymphoma cells.
    Kim JH; Lee JK
    Arch Pharm Res; 2015 Nov; 38(11):2042-8. PubMed ID: 26100136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Roles of NKG2D in cytokine-induced killer (CIK) against hematological malignant cells lines].
    He JY; Jia ZX; Cai XH; Han WM; Xiao R; Ma LD; Lu XZ; Zhou M; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1380-4. PubMed ID: 24370015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.
    Rettinger E; Kuçi S; Naumann I; Becker P; Kreyenberg H; Anzaghe M; Willasch A; Koehl U; Bug G; Ruthardt M; Klingebiel T; Fulda S; Bader P
    Cytotherapy; 2012 Jan; 14(1):91-103. PubMed ID: 21973023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple cytotoxic factors involved in IL-21 enhanced antitumor function of CIK cells signaled through STAT-3 and STAT5b pathways.
    Rajbhandary S; Zhao MF; Zhao N; Lu WY; Zhu HB; Xiao X; Deng Q; Li YM
    Asian Pac J Cancer Prev; 2013; 14(10):5825-31. PubMed ID: 24289584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines.
    Durrieu L; Lemieux W; Dieng MM; Fontaine F; Duval M; Le Deist F; Haddad E
    Cytotherapy; 2014 Jun; 16(6):845-56. PubMed ID: 24529554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triptolide induces mitochondria-mediated apoptosis of Burkitt's lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression.
    Kong J; Wang L; Ren L; Yan Y; Cheng Y; Huang Z; Shen F
    Toxicol Appl Pharmacol; 2018 Mar; 342():1-13. PubMed ID: 29407771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors.
    Hu L; Cao D; Li Y; He Y; Guo K
    Cancer Biol Ther; 2012 May; 13(7):516-26. PubMed ID: 22406996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dynamic transcriptomic atlas of cytokine-induced killer cells.
    Meng M; Li L; Li R; Wang W; Chen Y; Xie Y; Han R; Zhu K; Huang W; Yang L; Li S; Shi J; Tan W; Gao H; Zhao Y; Yang L; Tan J; Hou Z
    J Biol Chem; 2018 Dec; 293(51):19600-19612. PubMed ID: 30333226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.
    Li Y; Sharma A; Wu X; Weiher H; Skowasch D; Essler M; Schmidt-Wolf IGH
    Front Oncol; 2022; 12():713476. PubMed ID: 35646685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.